eCite Digital Repository

Familial hypercholesterolaemia: a model of care for Australasia


Watts, GF and Sullivan, DR and Poplawski, N and van Bockxmeer, F and Hamilton-Craig, I and Clifton, PM and O'Brien, R and Bishop, W and George, P and Barter, PJ and Bates, T and Burnett, JR and Coakley, J and Davidson, P and Emery, J and Martin, A and Farid, W and Freeman, L and Geelhoed, E and Juniper, A and Kidd, A and Kostner, K and Krass, I and Livingston, M and Maxwell, S and O'Leary, P and Owaimrin, A and Redgrave, TG and Reid, N and Southwell, L and Suthers, G and Tonkin, A and Towler, S and Trent, R, Familial Hypercholesterolaemia Australasia Network Consensus Group (Australian Atherosclerosis Society), Familial hypercholesterolaemia: a model of care for Australasia, Atherosclerosis Supplements, 12, (2) pp. 221-263. ISSN 1567-5688 (2011) [Refereed Article]

Copyright Statement

Copyright 2011 Elsevier Ireland Ltd

DOI: doi:10.1016/j.atherosclerosissup.2011.06.001


Familial hypercholesterolaemia (FH) is a dominantly inherited disorder present from birth that causes marked elevation in plasma cholesterol and premature coronary heart disease. There are at least 45,000 people with FH in Australia and New Zealand, but the vast majority remains undetected and those diagnosed with the condition are inadequately treated. To bridge this major gap in coronary prevention the FH Australasia Network (Australian Atherosclerosis Society) has developed a consensus model of care (MoC) for FH. The MoC is based on clinical experience, expert opinion, published evidence and consultations with a wide spectrum of stakeholders, and has been developed for use primarily by specialist centres intending starting a clinical service for FH. This MoC aims to provide a standardised, high-quality and cost-effective system of care that is likely to have the highest impact on patient outcomes. The MoC for FH is presented as a series of recommendations and algorithms focusing on the standards required for the detection, diagnosis, assessment and management of FH in adults and children. The process involved in cascade screening and risk notification, the backbone for detecting new cases of FH, is detailed. Guidance on treatment is based on risk stratifying patients, management of non-cholesterol risk factors, safe and effective use of statins, and a rational approach to follow-up of patients. Clinical and laboratory recommendations are given for genetic testing. An integrative system for providing best clinical care is described. This MoC for FH is not prescriptive and needs to be complemented by good clinical judgment and adjusted for local needs and resources. After initial implementation, the MoC will require critical evaluation, development and appropriate modification.

Item Details

Item Type:Refereed Article
Research Division:Biomedical and Clinical Sciences
Research Group:Cardiovascular medicine and haematology
Research Field:Cardiology (incl. cardiovascular diseases)
Objective Division:Health
Objective Group:Clinical health
Objective Field:Clinical health not elsewhere classified
UTAS Author:Bishop, W (Dr Warrick Bishop)
ID Code:118673
Year Published:2011
Web of Science® Times Cited:156
Deposited By:Menzies Institute for Medical Research
Deposited On:2017-07-18
Last Modified:2017-08-21

Repository Staff Only: item control page